-Live Mint Natco Pharma Ltd, which has started selling a generic version of Bayer AG’s patented cancer treatment Nexavar in India at a fraction of the price charged by the German firm, plans to use the so-called compulsory Licensing route to try and win the right to copy more patented drugs, said vice-chairman and chief executive officer Rajeev Nannapaneni. The Hyderabad-based company has already identified the patented drugs for which it will...

-The Economic Times The crisis of the euro, a current account deficit of over 4%, double-digit inflation, corruption in governance and a failing political system. It would not be unfair to say that these factors have combined in varying degrees at different times to lead to the conclusion that the globally-acclaimed India growth story seems to be heading for an unhappy ending. Many have labelled this - unfairly, I think - as...

-The Hindustan Times   To get a driver's licence, what you have to counter is nothing short of a licence raj. Your mammoth effort will not be enough to get you the licence to drive on Delhi's roads. However, like in Hogwarts School of Witchcraft and Wizardry, help is always given to those who ask for it. At transport department offices, this help comes in the form of touts.  Though the Delhi government had...

-Down to Earth Traders say Food Safety and Standards Act rolls out red carpet for multinationals The Food Safety and Standards Act (FSSA) of 2006 has not gone down well with food business operators. They say sections of the Act dealing with Licensing, registration, hygiene standards, penalty provisions and powers of food safety inspectors are “draconian”. FSSA, which came into force in August last year, replaces the Prevention of Food Adulteration Act (PFA)...

German drugmaker Bayer AG has demanded the withdrawal of the country's first compulsory licence given to Natco Pharma, arguing that a three-fourth reduction in the price of the anti-cancer drug by another Indian firm has made the permit redundant and its patent itself is vulnerable to being revoked. In March, India allowed Natco Pharma to legally make and sell a low-cost version of cancer drug Nexavar at 3% of the original...